Biocon Pharma receives USFDA approval for Dapagliflozin Tablets, 5 mg and 10 mg
Biocon Pharma, a subsidiary of Biocon, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for Dapagliflozin Tablets, 5 mg and 10 mg. The…
Ajanta Pharma shares rise 5% on Biocon weight-loss drug marketing pact
Biocon will supply Semaglutide to Ajanta Pharma for exclusive marketing in 23 countries and semi-exclusive marketing in three countries across Africa, West Asia, and Central Asia Shares of Ajanta Pharma…
Biocon Bets Big on Insulin, Eyes GLP-1 Drugs for Future Growth
Bengaluru – Biocon Biologics, the biopharmaceutical arm of Biocon Ltd, is strengthening its foothold in the global insulin market while making a decisive move into the booming GLP-1 drug segment.…
Biocon launches Rs 4,500-crore QIP; to issue 11.6% of equity base
Bengaluru-based biopharmaceutical firm Biocon on Monday launched a qualified institutions placement (QIP) to raise Rs 4,500 crore. As part of the offering, the firm will issue up to 139 million…
Biocon Q4 net profit surges 153%, biosimilars, generics drive growth
Biocon, India’s leading biopharmaceutical company, reported a 153 percent year-on-year (YoY) jump in net profit for the fourth quarter of FY25, led by strong performances in its biosimilars and generics…
All about Insulin Aspart that promted CBI to arrest Jt. Drug Controller of India
New Delhi: Dr. Eswara Reddy, Joint Drug Controller of India had been arrested by CBI on Monday last with an employee of Bengaluru-based pharmaceutical company, Biocon Biologics and others…
